



Published in final edited form as:

*Eur Urol.* 2015 December ; 68(6): 980–992. doi:10.1016/j.eururo.2015.04.010.

## A Literature Review of Renal Surgical Anatomy and Surgical Strategies for Partial Nephrectomy

Tobias Klatte<sup>a,\*</sup>, Vincenzo Ficarra<sup>b</sup>, Christian Gratzke<sup>c</sup>, Jihad Kaouk<sup>d</sup>, Alexander Kutikov<sup>e</sup>, Veronica Macchi<sup>f</sup>, Alexandre Mottrie<sup>g</sup>, Francesco Porpiglia<sup>h</sup>, James Porter<sup>i</sup>, Craig G. Rogers<sup>j</sup>, Paul Russo<sup>k</sup>, R. Houston Thompson<sup>l</sup>, Robert G. Uzzo<sup>e</sup>, Christopher G. Wood<sup>m</sup>, and Inderbir S. Gill<sup>n</sup>

<sup>a</sup>Department of Urology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria

<sup>b</sup>Department of Urology, University of Udine, Udine, Italy

<sup>c</sup>Department of Urology, Ludwig-Maximilians-University Munich, Munich, Germany

<sup>d</sup>Center for Advanced Laparoscopic and Robotic Surgery, Glickman Urologic and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA

<sup>e</sup>Department of Urological Oncology, Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, PA, USA

<sup>f</sup>Centre for Mechanics of Biological Materials, University of Padua, Padua, Italy

<sup>g</sup>OLV Robotic Surgery Institute, Aalst, Belgium

<sup>h</sup>Department of Urology, San Luigi Gonzaga Hospital-Orbassano, University of Turin, Turin, Italy

---

\*Corresponding author. Department of Urology, Medical University of Vienna, Vienna General Hospital, Währinger Gürtel 18–20, A-1090 Vienna, Austria. Tel. +43 1 40400-26150; Fax: +43 1 40400-23320. tobias.klatte@gmx.de (T. Klatte).

**Author contributions:** Tobias Klatte had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Study concept and design:** Klatte, Gill.

**Acquisition of data:** Klatte, Ficarra, Gratzke, Kaouk, Kutikov, Macchi, Mottrie, Porpiglia, Porter, Rogers, Russo, Thompson, Uzzo, Wood, Gill.

**Analysis and interpretation of data:** Klatte, Ficarra, Gratzke, Kaouk, Kutikov, Macchi, Mottrie, Porpiglia, Porter, Rogers, Russo, Thompson, Uzzo, Wood, Gill.

**Drafting of the manuscript:** Klatte.

**Critical revision of the manuscript for important intellectual content:** Klatte, Ficarra, Gratzke, Kaouk, Kutikov, Macchi, Mottrie, Porpiglia, Porter, Rogers, Russo, Thompson, Uzzo, Wood, Gill.

**Statistical analysis:** None.

**Obtaining funding:** None.

**Administrative, technical, or material support:** None.

**Supervision:** None.

**Other:** None.

**Financial disclosures:** Tobias Klatte certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending), are the following: None.

**Funding/Support and role of the sponsor:** None.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

<sup>i</sup>Swedish Urology Group, Seattle, WA, USA

<sup>j</sup>Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI, USA

<sup>k</sup>Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

<sup>l</sup>Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, MN, USA

<sup>m</sup>Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA

<sup>n</sup>University of Southern California Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA

## Abstract

**Context**—A detailed understanding of renal surgical anatomy is necessary to optimize preoperative planning and operative technique and provide a basis for improved outcomes.

**Objective**—To evaluate the literature regarding pertinent surgical anatomy of the kidney and related structures, nephrometry scoring systems, and current surgical strategies for partial nephrectomy (PN).

**Evidence acquisition**—A literature review was conducted.

**Evidence synthesis**—Surgical renal anatomy fundamentally impacts PN surgery. The renal artery divides into anterior and posterior divisions, from which approximately five segmental terminal arteries originate. The renal veins are not terminal. Variations in the vascular and lymphatic channels are common; thus, concurrent lymphadenectomy is not routinely indicated during PN for cT1 renal masses in the setting of clinically negative lymph nodes. Renal-protocol contrast-enhanced computed tomography or magnetic resonance imaging is used for standard imaging. Anatomy-based nephrometry scoring systems allow standardized academic reporting of tumor characteristics and predict PN outcomes (complications, remnant function, possibly histology). Anatomy-based novel surgical approaches may reduce ischemic time during PN; these include early unclamping, segmental clamping, tumor-specific clamping (zero ischemia), and unclamped PN. Cancer cure after PN relies on complete resection, which can be achieved by thin margins. Post-PN renal function is impacted by kidney quality, remnant quantity, and ischemia type and duration.

**Conclusions**—Surgical renal anatomy underpins imaging, nephrometry scoring systems, and vascular control techniques that reduce global renal ischemia and may impact post-PN function. A contemporary ideal PN excises the tumor with a thin negative margin, delicately secures the tumor bed to maximize vascularized remnant parenchyma, and minimizes global ischemia to the renal remnant with minimal complications.

**Patient summary**—In this report we review renal surgical anatomy. Renal mass imaging allows detailed delineation of the anatomy and vasculature and permits nephrometry scoring, and thus precise, patient-specific surgical planning. Novel off-clamp techniques have been developed that may lead to improved outcomes.

---

## 1. Introduction

The incidence of renal tumors has been increasing over the past several decades [1]. The majority of these tumors are diagnosed at clinical stage T1 [2] and are amenable to partial nephrectomy (PN), which is the accepted surgical treatment. More recently, minimally invasive PN has become a viable alternative to open PN (OPN) and is routinely performed at many centers worldwide [3]. Much effort has been made to integrate the anatomy of the renal mass and its vasculature into current concepts [4,5]. A detailed understanding of surgical anatomy is necessary to optimize preoperative planning and operative technique, thus providing a basis for maximizing oncologic and functional outcomes. The purpose of this article is to provide a contemporary overview of renal surgical anatomy and anatomy-based issues for PN surgery, such as imaging, nephrometry scoring systems, novel vascular control techniques that reduce global renal ischemia, and factors impacting post-PN function and oncologic outcomes.

## 2. Evidence acquisition

The Medline, Embase, and Web of Science databases were searched without time limit on August 1, 2014 using the terms “partial nephrectomy” OR “nephron-sparing surgery” in conjunction with “anatomy” (MeSH), “ischemia”, “renal function”, “margin”, “adrenalectomy”, “lymphadenectomy”, OR “complications”. Both free-text protocols and medical subject headings (MeSH) were used in Medline, while free-text protocols were run in Embase and Web of Science. Autoalerts in Medline were also run, and reference lists of original articles, review articles, and book chapters were searched for further eligible articles. The search was limited to the English literature. Articles that did not address the topics were excluded, and the full text of the remaining articles was reviewed. A list of articles that were judged to be highly relevant by the junior and senior authors was circulated among the coauthors, and a final consensus was reached on the structure of this review and the articles included. In addition, during writing of the manuscript, pertinent contemporary articles were identified in an attempt to include the most recent data.

## 3. Evidence synthesis

### 3.1. Surgical anatomy of the kidney

The right kidney is located approximately 1–2 cm lower than the left kidney because of the location of liver. The diaphragm covers the upper third of the kidneys posteriorly, where there is also a close relationship to the pleura that extends to the level of the 12th rib. Anteriorly, the right kidney is bordered by the liver and the right colonic flexure. The descending part of the duodenum with the head of pancreas overlies the right renal hilum. The left kidney is bordered anteriorly by the left colonic flexure. The left renal hilum is in close anatomic relation to the body of the pancreas and the splenic vessels. The upper pole of the kidneys abuts the adrenal gland, which may cap the kidney or cradle the renal hilum, especially on the left. The posterior aspect of the kidney lies on the psoas muscle [6]. Therefore, it is important to realize that the upper pole lies medially and in a posterior plane relative to the lower pole. Computed tomography (CT) slices are commonly recorded at a right angle to the body, but because of the aforementioned angulation of the kidney, this is

not necessarily at right angles to the kidney. Thus, an upper-pole tumor may occasionally appear on CT scan images as a mid-renal tumor. Therefore, for accurate imaging, appropriate adjustment of cross-sectional CT slices is required, taking into account the angulation of the kidney.

Gerota's fascia encloses the kidney, adrenal gland, and perinephric fat. Its layers are fused superiorly, laterally, and medially, but not inferiorly. Classically, the structures of the renal hilum are, from anterior to posterior, a single renal vein, a single renal artery, and the renal pelvis. The hilar region is rotated somewhat anteriorly because of the psoas muscle [7,8].

**3.1.1. Arterial system**—In approximately 75% of cases, a single renal artery arises bilaterally from the lateral portion of the abdominal aorta immediately caudal to the origin of the superior mesenteric artery. Duplication of renal arteries is more common on the right side (Fig. 1); duplicate arteries are often similar in caliber, with the exception of accessory renal arteries, which occur in approximately 25% of patients. These accessory arteries usually arise from the aorta and commonly subtend the poles. An accessory artery is defined as any supernumerary artery that reaches the kidney. If the artery does not enter the kidney at the hilum (eg, enters the parenchyma at a pole), it is called aberrant. An accessory artery may therefore be aberrant (but is not always so). Accessory arteries to the upper pole are typically smaller in diameter than those to the lower pole. The right renal artery passes behind the inferior vena cava (IVC) and is typically posterior and superior to the left and right renal veins. In approximately 30% of cases, the renal artery is located anterior to the renal vein. The left renal artery is higher than the right [6,9].

In relation to the renal pelvis, the renal artery forms an anterior division, which carries 75% of the blood supply, and a posterior division, which carries 25% of the blood supply. These divisions are most often formed outside the renal hilum [9]. Extra- and intraparenchymal arterial sections can be distinguished (Fig. 2). Along the lateral border of the kidney, between the arterial divisions, lies the avascular plane (Brödel's line), which is located in the axis of the posterior. This avascular plane is not in the exact mid-lateral portion of the kidney, but is located slightly posteriorly. Brödel's line can be used for avascular access for anatomic nephrolithotomy and for endophytic tumors.

From the arterial divisions, five segmental arteries originate, including an apical, upper, middle, lower, and posterior segmental artery (Fig. 3) [10]. The first four segmental arteries arise from the anterior division, and the last segmental branch arises from the posterior division. Segmental arteries are end arteries and do not provide adequate collateral circulation. Ligation of a segmental artery causes irreversible ischemia to that segment of the kidney and subsequent segmental renal infarction. This involves limited parenchymal areas in the case of an anterior segmental artery, but occlusion of the posterior segmental artery can result in infarction of almost the entire posterior aspect of the kidney. A high percentage of patients shows anatomic variants of Graves' initial classification [10], especially for the lower segmental artery, which may arise from the main renal artery, its anterior division, the upper segmental artery, or as an accessory artery from the abdominal aorta [6]. Segmental arteries give rise to interlobar arteries at the level of the fornix, and these continue in the interlobar septae between the pyramids. At the corticomedullary junction, each interlobar

artery branches into five to seven arcuate arteries, which in turn branch into interlobular arteries. Interlobular arteries supply the afferent glomerular arteries.

**3.1.2. Venous system**—The peritubular capillary venous plexus drains through venae rectae into the arcuate veins. Similar to the arterial system, arcuate veins drain into the interlobular vein, which forms several trunks (two in ~50%, three in ~30% of cases) that unite as the renal vein anterior to the renal pelvis. Anastomotic longitudinal venous arcades are present within the kidney. These veins are not terminal, so the major branches can be surgically ligated without the risk of venous obstruction. A retropelvic vein, which drains some of the posterior part of the kidney, is present in two-thirds of cases [6].

The right renal vein drains directly into the IVC. There are usually no tributaries; rarely, the right gonadal vein may drain into the right renal vein. Duplication is found in 15–20% of cases. In contrast to the arterial system, isolated accessory polar veins are a rarity. The left renal vein is approximately two to three times longer than the right renal vein, enters the IVC anterior to the aorta, and is infrequently duplicated. In such instances, a retroaortic left renal vein may be present, and is often circumaortic to reflect branches anterior and posterior to the aorta. Left renal vein tributaries include the gonadal vein, adrenal vein, inferior phrenic veins, the first or second lumbar veins, and paravertebral veins in one-third of cases. The rich anastomotic structure makes it possible to ligate the left renal vein medially via IVC occlusion in the case of an IVC thrombus for a right-sided renal cell carcinoma (RCC) or during surgery for an abdominal aortic aneurysm [6].

**3.1.3. Radially oriented intrarenal architecture**—The intrarenal anatomy is radially oriented. This fact can be taken advantage of when performing PN. The intrarenal arteries, veins, and calyces fan out radially from the renal hilar sinus towards the lateral convex border of the kidney. Thus, a radial nephrotomy incision during unclamped PN is less likely to transect a major intrarenal vessel, and may therefore result in less bleeding than for a nonradial incision. In addition, the renal parenchyma and pyramids are similarly radially oriented. Therefore, during enucleative PN, an appropriate enucleative plane can typically be identified and then developed bluntly in close vicinity to the tumor capsule. This radially oriented parenchyma lends itself to atraumatic blunt separation of the renal parenchyma rather than sharp cutting.

**3.1.4. Kidney tumor-parenchyma interface**—During enucleative PN, excision is performed immediately adjacent to the tumor edge. To better inform the anatomic and oncologic propriety of enucleative PN, histologic examination of the tumor-parenchyma interface was performed on 124 nephrectomy specimens [11]. Some 82% of malignant tumors had an intrarenal pseudocapsule (PC) with a median thickness of 0.6 mm. PC invasion was noted in 45% of the cancers overall; however, no patient had a positive surgical margin. Inflammation, nephrosclerosis, glomerulosclerosis, and arteriosclerosis decreased with increasing distance from the tumor edge. The mean arteriolar diameter decreased with tumor proximity. The authors concluded that PN excision adjacent to the tumor edge appears to be histologically safe. Since the peritumoral parenchyma is histologically altered/compressed with fewer/smaller arterioles, this appears to be a surgically favorable plane for enucleative PN. Since 18% of cancers lacked an intrarenal PC and 25% of pT1a cancers had

intrarenal PC invasion, extreme care is necessary to avoid positive margins during enucleative PN [11].

### 3.2. Partial nephrectomy planning

**3.2.1. Imaging of renal tumors and the vascular system**—An understanding of the renal anatomy and vasculature is necessary for preoperative surgical planning. Imaging must delineate the relationship of the mass to adjacent normal structures and demonstrate the vascularity of the tumor.

Bi- or triphasic contrast-enhanced CT of the abdomen is the reference standard for primary imaging and staging. According to the American College of Radiology Practice Guidelines, the CT slice thickness should be 5 mm or less [12]. Masses are classified as solid or cystic, with subclassification of the latter according to Israel and Bosniak [13]. The multidetector CT (MDCT) protocol includes a non-contrast phase, a corticomedullary phase (after 40 s), a nephrographic phase (90 s), and a urographic phase (7 min). Enhancement of >15–20 Hounsfield units (HU) is considered the most important indicator of malignancy and is best assessed in the nephrographic phase. The corticomedullary phase is used to assess the arterial system (number of renal arteries, feeding mass arteries) and the urographic phase to assess proximity to and involvement of the renal collecting system [14]. Three-dimensional CT reconstruction depicts the vascular and renal mass anatomy in a format familiar to surgeons and serves to guide PN surgery, especially in complex cases [15,16].

Although CT remains the standard for primary imaging of renal masses, it has limited ability to characterize masses of <1 cm in diameter and carries radiation exposure [14]. Dual-energy CT (DECT) has the potential to lower radiation exposure by approximately 50%. DECT involves simultaneous acquisition of CT data at two different energy settings. Different materials show distinct attenuation levels at a given energy setting, allowing for material decomposition [14]. If iodine is removed from the post-contrast image, a virtual non-contrast image is acquired. For characterization of renal masses, DECT has similar accuracy to conventional two-phase CT examinations with a true non-contrast phase [17]. Although initial data are convincing, DECT technology is not yet broadly available and further data are required.

Macroscopic fat (less than –20 HU) can generally be observed on CT scans of angiomyolipomas, so these can be differentiated from other renal tumors. It is important to note that the fat content may be difficult to diagnose in small angiomyolipomas because of the volume averaging effect and a proportion of angiomyolipomas are fat-poor. Oncocytomas are typically hypervascular and homogeneous and may have a characteristic central stellate scar; however, CT features cannot reliably distinguish an oncocytoma from other renal tumors [18]. Papillary and chromophobe RCCs generally exhibit lower and more heterogeneous enhancement than clear-cell RCC [19,20], but subtypes are more difficult to differentiate in small masses. In terms of tumor size, studies indicate that CT imaging overestimates pathologic size by a small amount. The size tends to be overestimated small tumors and underestimated for larger tumors [21].



Magnetic resonance imaging (MRI) is an alternative imaging procedure and is commonly used as a problem-solving tool in patients with indeterminate CT scans (eg, for complex cystic lesions, very small masses, enhancement of 10–20 HU) or contrast medium allergies [22]. Compared to CT, MRI may be better for detecting perirenal fat invasion and evaluating the cranial and caudal extent of a venous thrombus in the IVC, as well as delineating benign thrombus from tumor thrombus [14]. Functional and advanced imaging techniques such as diffusion-weighted and perfusion-weighted imaging are expected to expand the role of MRI in the future [23].

Renal ultrasound can distinguish cystic from solid masses, may assist in identifying angiomyolipoma, and can show vascularity with the additional use of ultrasound contrast agents, including microbubbles. Because it is both less accurate than CT or MRI and user-dependent, ultrasound has a limited role in preoperative surgical planning [24]. Furthermore, assessment of the IVC and retroperitoneal nodes is often limited by bowel gas and body habitus [14]. Intraoperative ultrasound is most commonly used for intraoperative localization, to screen for additional small lesions, to confirm ischemia following clamping, to assist in obtaining negative resection margins during PN, to enable renal mass biopsy, and to guide probe placement for thermal ablation. Intraoperative ultrasound reveals additional findings not observed on preoperative imaging in approximately 10% of patients undergoing PN. This alters surgical management in the majority of cases [25].

**3.2.2. Nephrometry scoring systems**—Anatomy-based nephrometry scores are assigned from preoperative imaging and delineate renal mass characteristics and the relationship to adjacent structures [26]. Use of standardized objective and reproducible measures minimizes interobserver variability. Nephrometry scores can inform the surgeon regarding technical difficulty during PN for a given mass, and have been correlated with ischemia time, operation time, blood loss, complications, and the likelihood of conversion from PN to radical nephrectomy (RN). Nephrometry scoring systems can assist in clinical decision-making on RN versus PN or open versus minimally invasive PN [27].

**3.2.2.1. RENAL score:** The RENAL nephrometry score consists of five anatomic radiologic properties: (R)adius/maximal tumor diameter, (E)xophytic/endophytic properties, (N)earness to the collecting system or sinus, (A)nterior(a)/posterior(p)/not anterior or posterior (x) descriptor, and (L)ocation relative to the polar line. The polar lines are defined by the planes in which the medial lip of parenchyma is first seen. The suffix hilar (h) is added for tumors that abut the main renal artery or vein (Table 1) [28].

For each variable except A, one to three points are assigned, which yield a total of 3 points for the least complex and 12 points for the most complex mass. The score is read as each individual variable (eg, 1 + 2 + 2 + A + 3) summed to a score and followed by the polar location (eg, 8A). Masses are classified as low complexity (RENAL score 4–6), moderate complexity (score 7–9), or high complexity (score 10–12). An online tool has been developed to facilitate calculation at the point of care ([www.nephrometry.com](http://www.nephrometry.com)).

**3.2.2.2. PADUA classification:** The Preoperative Aspects and Dimensions Used for an Anatomical (PADUA) classification consists of six scoring parameters and an anterior/

posterior descriptor. The variables include polar location, exophytic/endophytic rate, renal rim, involvement of the renal sinus, involvement of the urinary collecting system, and maximal tumor size (Table 1) [29]. The polar lines are defined as the upper and lower margins of the renal sinus fat. The classification is given as a single sum of these parameters, with a minimum score of 6 and a maximum of 14. Stratification may be according to low complexity (score 6–7), moderate complexity (score 8–9), or high complexity (score 10–14) given the fact that this correlates with the risk of overall complications [29].

**3.2.2.3. Centrality index:** The centrality index (CI) differs substantially from the RENAL score and PADUA classification. CI is a continuous index based on tumor size and distance from the periphery of the tumor to the center of the kidney [30], which are thought to be the most important factors that determine resection difficulty. CI is defined as the ratio of  $c$  to the tumor radius  $r$  (diameter/2). The variable  $c$  equalizes the distance from the tumor center to the kidney center and may be calculated according to the Pythagorean theorem on axial images. For a tumor in the kidney center,  $CI = 0$ . CI increases with increasing distance of the tumor periphery from the kidney center, and surgical resection becomes easier. An online spreadsheet facilitating CI calculations is available (<http://my.clevelandclinic.org/Documents/Urology/CentralityIndex2.xls>).

**3.2.2.4. Contact surface area:** The larger the surface area of contact between a tumor and its surrounding uninvolved renal parenchyma, the greater are the amount of kidney tissue excised and the extent of renorrhaphy required during PN surgery. Contact surface area (CSA) is a descriptive, CT-based radiologic data point that may better reflect tumor complexity by numerically combining two important aspects, tumor size and percentage endophytic component, into a single radiologically measurable parameter. Using three-dimensional rendering software, the tumor circumference and its intraparenchymal component are manually rendered. Image-processing software then automatically calculates the volume of the tumor and its intraparenchymal component. The total surface area (TSA) of the tumor is calculated using the formula  $4\pi r^2$  ( $r$  = tumor radius). CSA is derived by multiplying TSA by the percentage intraparenchymal component. For 162 tumors,  $CSA > 20 \text{ cm}^2$  predicted adverse tumor characteristics (greater tumor size, volume, complexity) and perioperative outcomes (more parenchymal volume loss, blood loss, complications) compared to  $CSA < 20 \text{ cm}^2$ . Interobserver concordance of CSA was excellent [31].

**3.2.2.5. Summary of studies on nephrometry scoring systems:** As shown in Table 1, there are few differences in the RENAL and PADUA scores for a given renal mass. The scores are highly correlated (correlation coefficient 0.8) [32]. Both systems assign almost the same points for maximal tumor size. The only difference is for a tumor with a maximal size of 7.0 cm, which would be scored as 2 according to RENAL and 3 according to PADUA. In the PADUA classification, the renal sinus and collecting system are scored separately on a scale of 1–2, compared to a single three-tiered variable in the RENAL system. Because of differing definitions of polar lines, the polar location may be assigned differently (Table 1). The two systems show good agreement, with correlation of 0.7–0.9 [33–37]. Although CI contains only two variables, the coefficients for correlation with the RENAL and PADUA scores are remarkable (0.4–0.6) [32]. While CSA correlates well with the RENAL, PADUA,



and CI systems, initial data suggest that CSA may be more accurate in predicting certain perioperative events [31].

There have been numerous studies on nephrometry scoring systems. Detailed descriptions are beyond the scope of this article. Although there are conflicting data, the majority of studies indicate that the systems are similarly effective in predicting the risk of overall complications, estimated blood loss, length of hospital stay, and ischemia time (Table 2). Several reports have correlated nephrometry scores with postoperative renal function [32,34,38]. Nephrometry parameters have been associated with pathological factors. Based on parameters of the RENAL score, nomograms predicting malignancy and high grade were developed [39]. For both nomograms, maximal tumor size (variable R) was the most important nephrometric variable. The area under the curve was 73% and 76% for malignancy and high grade, respectively. External validation revealed an area under the curve of 73% for prediction of high-grade disease [40]. Likewise, recent studies showed that higher tumor complexity according to the RENAL score is associated with high-grade disease and clear-cell subtype [41,42].

### 3.3. Optimizing PN outcomes

**3.3.1. Optimizing functional outcomes of PN**—Multiple factors impact renal functional outcomes after PN, including preoperative renal function, comorbidity, age, gender, tumor size, percentage volume preservation, and ischemia time [43]. Overall, the two surgically relevant principles for optimizing post-PN functional outcomes are to maximize volume preservation and minimize ischemia. The volume of parenchyma preserved is potentially more important than short-duration ischemia time, especially in healthy patients with normal function at baseline [44,45].

**3.3.1.1. Maximizing volume preservation:** As discussed in Section 3.3.2, the margin width should be minimized while ensuring a negative margin [3]. Generalized through-and-through oversuturing of the PN bed may be minimized to reduce ischemic damage to adjacent healthy remnant parenchyma, although this concept has not been proven. Suturing of the PN bed may even be avoided in selected cases [46]. There are several methods available to evaluate the amount of renal parenchyma preserved. Subjective surgeon assessment of preserved volume may provide an estimate comparable to more time-consuming imaging techniques, including cylindrical measurements obtained from preoperative and postoperative CTs [47] or three-dimensional imaging [48].

**3.3.1.2. Minimizing ischemia:** During PN, the main artery is routinely clamped to minimize blood loss and create a relatively bloodless field for tumor excision and renal reconstruction. However, arterial clamping leads to ischemic damage of the renal parenchyma. Several models have been proposed to study the effects of ischemia on renal function, such as the solitary kidney [49]. There is no agreement on the precise cutoff time for the onset of durable renal damage during warm ischemia [50–53]. Ischemia time should be interpreted as a continuum whereby increasingly prolonged ischemia times are more likely to cause acute kidney dysfunction [49,53]. A recent report indicated that patients with baseline medical chronic kidney disease had worse long-term outcomes after PN than those with surgically

induced chronic kidney disease [54]. Elderly patients with comorbidities (diabetes, hypertension) and pre-existing renal dysfunction at baseline are likely to have compromised kidneys with glomerulonephro-arteriosclerosis due to medical renal disease. These compromised kidneys are probably more acutely susceptible to even shorter ischemic insults compared to healthy younger individuals with normal kidney function at baseline. Thus, recent efforts continue to be directed towards minimizing ischemic injury.

The classical strategy to limit ischemic damage is the induction of hypothermia (cold ischemia). Surface cooling with ice slush decreases renal energy expenditure and partly ameliorates the adverse impact of warm ischemia and reperfusion injury [55,56]. A nonrandomized comparative study revealed a similar decrease in glomerular filtration rate (GFR) at 3 mo after warm or cold ischemia, although the median cold ischemia time was substantially longer (45 vs 22 min) [44]. Many surgeons prefer to use mannitol and/or furosemide during PN, which may optimize reperfusion and increase diuresis [57]. However, several recent studies do not support the use of mannitol during PN [58], even in solitary kidneys [59]. Cooling with ice slush is the classical strategy for cold ischemia during OPN [56], but has also been applied in minimally invasive approaches [60,61].

As routine induction of cold ischemia is still technically arduous, several anatomic methods have been proposed to reduce the extent and duration of warm ischemia. From a practical perspective, the most technically relevant, surgically modifiable factor that impacts remnant function after PN is the duration or extent of ischemia. Global renal ischemia time is significantly reduced by early unclamping of the main renal artery, which is performed immediately after placement of the initial central running suture [62]. Compared to standard clamping in PN, warm ischemia times are reduced by >50% (mean 31.1 vs 13.9 min), while estimated blood loss and bleeding complications are similar [62]. In another study, mean warm ischemia time was reduced from 28 to 18.5 min [63].

Clamping of the main artery results in the greatest ischemic insult, which can be reduced by selective clamping of only the pertinent segmental artery(ies) [64]. The selective clamping technique is primarily used in minimally invasive PN, but Nohara et al [65] were also able to apply selective arterial clamping during OPN; however, a segmental renal artery could be isolated in only half of cases. Selective arterial clamping may not be feasible in certain instances such as dense or adherent perirenal fat or short segmental arteries [64].

Clamping of distally located, tumor-specific, higher-order segmental renal artery branches in minimally invasive PN has been described [66]. Zero-ischemia PN refers to superselective clamping of tumor-specific tertiary or quaternary artery branches. In another series, this was performed successfully in 84% of patients undergoing laparoscopic PN (LPN). Compared to clamping of the main renal artery, blood loss was greater (238 vs 154 ml), but patients who had segmental renal artery clamping had significantly better renal function at 3–6 mo [67,68]. Since arterial blood flow to the remnant kidney is not interrupted, global renal ischemia is eliminated [69,70]. Tumor-specific arterial branches are microdissected and superselectively clamped with micro-bulldog clips. Selective arterial control is confirmed intraoperatively by color Doppler sonography [69,70], hyperspectral imaging [71,72], or robotic vascular fluorescence imaging [73]. In an initial study of 15 patients, there was no

change in estimated GFR (eGFR) [66]. Additional studies showed that the ipsilateral renal function decreased by approximately 10% [74]. The rate of major and minor complications was 0% and 18%, respectively [70], which is comparable to other techniques. Oncologic control with negative surgical margins was achieved in all patients [66,70,74]. Zero-ischemia minimally invasive PN appears best suited for medially located or hilar tumors [66].

If the tumor has favorable anatomic features (small size, exophytic lesion, low nephrometry scores), PN may be performed without any vascular clamping whatsoever. Tumor excision and renal reconstruction are performed unclamped. This approach can reduce the incidence of acute renal failure in patients with a solitary kidney [75]. There have been several studies on this approach; the majority of tumors were removed by OPN [76,77]. In one report on 101 patients, LPN was performed without clamping and suturing; however, more than 95% of the tumors had low nephrometry scores. Split-renal functional outcomes at 1 yr were unchanged from preoperative data [46]. Studies revealed an increase in estimated blood loss for this approach without an increase in transfusion rates [78], whereas others seemed to show increased transfusion rates [77]. Clampless minimally invasive PN may be aided by prior superselective embolization of tumor-specific arteries [79,80], prior radiofrequency ablation [81], and parenchymal clamping [82] in select cases. In minimally invasive PN for selected tumors, a bolster can be omitted [83]. The defect can be closed with an intraparenchymal running suture and thrombin sealant. This obviates the need for parenchymal renorrhaphy suturing and shortens ischemia time.

The issue of improving renal functional outcomes by decreasing warm ischemia time is not yet settled. Several studies indicate that the amount of renal parenchyma preserved, but not the type or duration of ischemia, is significant in multivariate analysis [44,45]. Conversely, a recent report indicated that decreasing warm ischemia times resulted in superior renal functional outcomes after correcting for volume loss. In serial cohorts with similar preserved parenchyma volumes and ischemia times of 36, 32, 15, and 0 min, actual eGFR outcomes exceeded volume-predicted eGFR outcomes only in the zero-ischemia cohort (−9.5%, −11%, −0.9%, and +4.2%, respectively;  $p < 0.001$ ) [84]. Further prospective studies are necessary to clarify this issue.

**3.3.2. Optimizing oncologic outcomes of PN**—Positive surgical margins occur in approximately 3% of cases after PN [85]. Historically, a 1-cm rim of healthy parenchyma was recommended to allow optimal local tumor control [86]. The width of the negative margin does not affect local tumor control [87]. In patients with a positive margin, only 7% of reoperated renal remnants had viable cancer cells [88]. Thus, the width of the negative margin can be kept to a thin, uniform rim of normal parenchyma. Intraoperative frozen section analysis is not definitive and has limited clinical significance [89], so can be omitted in the setting of complete gross resection.

Enucleative PN (tumor enucleation) along the natural plane between the tumor PC and renal parenchyma is an alternative approach for preserving the maximal amount of renal parenchyma [90]. There have been some doubts regarding local tumor control, but data from nonrandomized observational studies indicate similar oncologic outcomes compared to RN in appropriately selected patients [91]. However, it is noteworthy that some tumors do not

have a PC, and thus may not qualify for enucleation [92]. Even if the tumor penetrates through the pseudocapsule in healthy parenchyma, enucleation with a negative margin status can be achieved [93]. Enucleation may be accompanied by diathermy or laser ablation of the tumor bed.

**3.3.3. Minimizing PN complications**—The two main procedure-related renal complications of PN are hemorrhage and urinary leakage. Risk factors for complications can be classified as anatomic, surgical, or patient-related. Anatomic risk factors are summarized in the nephrometry scoring systems, which correlate with the overall risk for complications [94–96]. Anatomic and patient-related factors cannot be modified, but can guide the surgical approach.

The incidence of complications is well documented in the prospective EORTC 30904 trial. Perioperative blood loss was <0.5 l in 17.1%, 0.5–1.0 l in 9.7%, and >1.0 l in 3.1% of cases [97]. In addition to coagulopathy and intraoperative vascular injuries as patient-related and surgical risk factors, proximity to the collecting system [95] and tumor size [98] are established anatomic risk factors for perioperative hemorrhage (intra- and postoperative). In a multicenter study of 730 elective OPNs, the rate of blood transfusions for tumors  $\leq 4$  cm and >4 cm was 6.3% and 14.8%, respectively [98]. ASA score  $\geq 3$  (OR 2.9) and smoking (OR 3.5) were identified as additional patient-related risk factors for blood transfusion following LPN [99]. LPN appears to be associated with lower intraoperative blood loss, but a higher rate of postoperative hemorrhage [100]. Most patients with postoperative hemorrhage can be managed conservatively; some require embolization and a minority need reoperation [100,101]. Precise operative technique and intraoperative hemostasis are cornerstones in preventing postoperative hemorrhage. Hemostatic agents and tissue sealants are frequently used as an adjunct to conventional hemostasis by coagulation and suturing, especially after LPN [102]. They improve hemostasis [103,104], but there is a lack of data from randomized studies.

Urinary leakage occurs in approximately 4–5% of cases [97,105]. Proximity to the collecting system, and thus a higher nephrometry score, is associated with postoperative urinary leakage [106]. Tumor size is another main risk factor, with the incidence increasing twofold for tumors >2.5 cm [105]. Urinary leakage can be managed conservatively with a ureteral stent or percutaneous drainage [101]. Preoperative insertion of a ureteral catheter allows retrograde filling to identify opening of the urinary collecting system, although this did not decrease the rate of postoperative urine leaks [107]. A renal pelvic anatomy score (RPS) has been developed [108] and validated [96,109]. The RPS is defined as the percentage of renal pelvis inside the renal parenchyma volume, categorized as intraparenchymal (>50%) or extraparenchymal (<50%) renal pelvis. Intraparenchymal renal pelvic anatomy is associated with a markedly higher risk of urinary leakage, which in turn may guide perioperative management [108,109].

Reporting of composite outcomes of PN using a trifecta system (negative margins, functional preservation, no urologic complications) has recently been proposed and is likely to increase in relevance [84]. Importantly, the definition of trifecta outcomes is not standardized and several different criteria have been used [84,110,111].

## 4. Conclusions

Over the past decade, PN surgery has been evolving towards an ideal PN. Renal mass imaging allows detailed delineation of the anatomy and vasculature and permits nephrometry scoring, and thus precise, patient-specific surgical planning. Novel techniques have been developed that minimize global renal ischemia during PN. A contemporary ideal PN excises the tumor with a thin negative margin, precisely secures the tumor bed, and reduces global ischemia to the renal remnant with minimal complications.

## References

1. Ljungberg B, Campbell SC, Choi HY, et al. The epidemiology of renal cell carcinoma. *Eur Urol.* 2011; 60:615–21. [PubMed: 21741761]
2. Kane CJ, Mallin K, Ritchey J, Cooperberg MR, Carroll PR. Renal cell cancer stage migration: analysis of the National Cancer Data Base. *Cancer.* 2008; 113:78–83. [PubMed: 18491376]
3. Ljungberg B, Cowan NC, Hanbury DC, et al. EAU guidelines on renal cell carcinoma: the 2010 update. *Eur Urol.* 2010; 58:398–406. [PubMed: 20633979]
4. Patil MB, Lee DJ, Gill IS. Eliminating global renal ischemia during partial nephrectomy: an anatomical approach. *Curr Opin Urol.* 2012; 22:83–7. [PubMed: 22223066]
5. Ukimura O, Nakamoto M, Gill IS. Three-dimensional reconstruction of renovascular-tumor anatomy to facilitate zero-ischemia partial nephrectomy. *Eur Urol.* 2012; 61:211–7. [PubMed: 21937162]
6. MacLennan, GT. Kidney, ureter, and adrenal glands. In: MacLennan, GT., editor. *Hinman's atlas of urosurgical anatomy.* 2. Philadelphia, PA: Elsevier Saunders; 2012. p. 153-210.
7. Kaye KW, Goldberg ME. Applied anatomy of the kidney and ureter. *Urol Clin North Am.* 1982; 9:3–13. [PubMed: 7080291]
8. Sampaio FJ. Renal anatomy. Endourologic considerations. *Urol Clin North Am.* 2000; 27:585–607. [PubMed: 11098758]
9. Rocco, F.; Cozzi, G. Renal anatomy, physiology and its clinical relevance to partial nephrectomy. In: Patel, VR., editor. *Robotic urologic surgery.* London: Springer; 2012. p. 277-86.
10. Graves FT. The anatomy of the intrarenal arteries and its application to segmental resection of the kidney. *Br J Surg.* 1954; 42:132–9. [PubMed: 13209036]
11. Azhar RA, de Castro Abreu AL, Broxham E, et al. Histological analysis of the kidney tumor-parenchyma interface. *J Urol.* 2015; 193:415–22. [PubMed: 25111913]
12. American College of Radiology. Practice guideline: CT abdomen and pelvis. Reston, VA: ACR; 2011.
13. Israel GM, Bosniak MA. An update of the Bosniak renal cyst classification system. *Urology.* 2005; 66:484–8. [PubMed: 16140062]
14. Kang SK, Chandarana H. Contemporary imaging of the renal mass. *Urol Clin North Am.* 2012; 39:161–70. [PubMed: 22487759]
15. Coll DM, Uzzo RG, Herts BR, Davros WJ, Wirth SL, Novick AC. 3-Dimensional volume rendered computerized tomography for preoperative evaluation and intraoperative treatment of patients undergoing nephron sparing surgery. *J Urol.* 1999; 161:1097–102. [PubMed: 10081846]
16. Wunderlich H, Reichelt O, Schubert R, Zermann DH, Schubert J. Preoperative simulation of partial nephrectomy with three-dimensional computed tomography. *BJU Int.* 2000; 86:777–81. [PubMed: 11069400]
17. Chandarana H, Megibow AJ, Cohen BA, et al. Iodine quantification with dual-energy CT: phantom study and preliminary experience with renal masses. *Am J Roentgenol.* 2011; 196:W693–700. [PubMed: 21606256]
18. Choudhary S, Rajesh A, Mayer NJ, Mulcahy KA, Haroon A. Renal oncocytoma: CT features cannot reliably distinguish oncocytoma from other renal neoplasms. *Clin Radiol.* 2009; 64:517–22. [PubMed: 19348848]

19. Vikram R, Ng CS, Tamboli P, et al. Papillary renal cell carcinoma: radiologic-pathologic correlation and spectrum of disease. *Radiographics*. 2009; 29:741–54. [PubMed: 19448113]
20. Zhang J, Lefkowitz RA, Ishill NM, et al. Solid renal cortical tumors: differentiation with CT. *Radiology*. 2007; 244:494–504. [PubMed: 17641370]
21. Kathrins M, Caesar S, Mucksavage P, Guzzo T. Renal mass size: concordance between pathology and radiology. *Curr Opin Urol*. 2013; 23:389–93. [PubMed: 23778129]
22. Coll DM, Smith RC. Update on radiological imaging of renal cell carcinoma. *BJU Int*. 2007; 99:1217–22. [PubMed: 17441914]
23. Gilet AG, Kang SK, Kim D, Chandarana H. Advanced renal mass imaging: diffusion and perfusion MRI. *Curr Urol Rep*. 2012; 13:93–8. [PubMed: 22081252]
24. Kang SK, Kim D, Chandarana H. Contemporary imaging of the renal mass. *Curr Urol Rep*. 2011; 12:11–7. [PubMed: 20949339]
25. Bhosale PR, Wei W, Ernst RD, et al. Intraoperative sonography during open partial nephrectomy for renal cell cancer: does it alter surgical management? *Am J Roentgenol*. 2014; 203:822–7. [PubMed: 25247947]
26. Lieser G, Simmons MN. Developments in kidney tumor nephrometry. *Postgrad Med*. 2011; 123:35–42. [PubMed: 21566414]
27. Canter D, Kutikov A, Manley B, et al. Utility of the R.E.N.A.L. nephrometry scoring system in objectifying treatment decision-making of the enhancing renal mass. *Urology*. 2011; 78:1089–94. [PubMed: 22054378]
28. Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. *J Urol*. 2009; 182:844–53. [PubMed: 19616235]
29. Ficarra V, Novara G, Secco S, et al. Preoperative aspects and dimensions used for an anatomical (PADUA) classification of renal tumours in patients who are candidates for nephron-sparing surgery. *Eur Urol*. 2009; 56:786–93. [PubMed: 19665284]
30. Simmons MN, Ching CB, Samplaski MK, Park CH, Gill IS. Kidney tumor location measurement using the C index method. *J Urol*. 2010; 183:1708–13. [PubMed: 20299047]
31. Leslie S, Gill IS, de Castro Abreu AL, et al. Renal tumor contact surface area: a novel parameter for predicting complexity and outcomes of partial nephrectomy. *Eur Urol*. 2014; 66:884–93. [PubMed: 24680360]
32. Bylund JR, Gayheart D, Fleming T, et al. Association of tumor size, location, R.E.N.A.L. PADUA and centrality index score with perioperative outcomes and postoperative renal function. *J Urol*. 2012; 188:1684–9. [PubMed: 22998902]
33. Hew MN, Baseskioglu B, Barwari K, et al. Critical appraisal of the PADUA classification and assessment of the R.E.N.A.L. nephrometry score in patients undergoing partial nephrectomy. *J Urol*. 2011; 186:42–6. [PubMed: 21571340]
34. Okhunov Z, Rais-Bahrami S, George AK, et al. The comparison of three renal tumor scoring systems: C-Index, P.A.D.U.A., and R.E.N.A.L. nephrometry scores. *J Endourol*. 2011; 25:1921–4. [PubMed: 21905850]
35. Lavallée LT, Desantis D, Kamal F, et al. The association between renal tumour scoring systems and ischemia time during open partial nephrectomy. *Can Urol Assoc J*. 2013; 7:E207–14. [PubMed: 22630339]
36. Png KS, Bahler CD, Milgrom DP, Lucas SM, Sundaram C. The role of R.E.N.A.L. nephrometry score in the era of robot assisted partial nephrectomy. *J Endourol*. 2013; 27:304–8. [PubMed: 22967057]
37. Weight CJ, Atwell TD, Fazzio RT, et al. A multidisciplinary evaluation of inter-reviewer agreement of the nephrometry score and the prediction of long-term outcomes. *J Urol*. 2011; 186:1223–8. [PubMed: 21849200]
38. Simmons MN, Hillyer SP, Lee BH, Fergany AF, Kaouk J, Campbell SC. Nephrometry score is associated with volume loss and functional recovery after partial nephrectomy. *J Urol*. 2012; 188:39–44. [PubMed: 22578726]



39. Kutikov A, Smaldone MC, Egleston BL, et al. Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL nephrometry score. *Eur Urol.* 2011; 60:241–8. [PubMed: 21458155]
40. Wang HK, Zhu Y, Yao XD, et al. External validation of a nomogram using RENAL nephrometry score to predict high grade renal cell carcinoma. *J Urol.* 2012; 187:1555–60. [PubMed: 22425078]
41. Satasivam P, Sengupta S, Rajarubendra N, Chia PH, Munshey A, Bolton D. Renal lesions with low R.E.N.A. L nephrometry score are associated with more indolent renal cell carcinomas (RCCs) or benign histology: findings in an Australian cohort. *BJU Int.* 2012; 109(Suppl 3):44–7. [PubMed: 22458493]
42. Mullins JK, Kaouk JH, Bhayani S, et al. Tumor complexity predicts malignant disease for small renal masses. *J Urol.* 2012; 188:2072–6. [PubMed: 23083863]
43. Lane BR, Babineau DC, Poggio ED, et al. Factors predicting renal functional outcome after partial nephrectomy. *J Urol.* 2008; 180:2363–8. [PubMed: 18930264]
44. Lane BR, Russo P, Uzzo RG, et al. Comparison of cold and warm ischemia during partial nephrectomy in 660 solitary kidneys reveals predominant role of nonmodifiable factors in determining ultimate renal function. *J Urol.* 2011; 185:421–7. [PubMed: 21167524]
45. Simmons MN, Hillyer SP, Lee BH, Fergany AF, Kaouk J, Campbell SC. Functional recovery after partial nephrectomy: effects of volume loss and ischemic injury. *J Urol.* 2012; 187:1667–73. [PubMed: 22425124]
46. Simone G, Papalia R, Guaglianone S, Gallucci M. “Zero ischaemia”, sutureless laparoscopic partial nephrectomy for renal tumours with a low nephrometry score. *BJU Int.* 2012; 110:124–30. [PubMed: 22177008]
47. Simmons MN, Fergany AF, Campbell SC. Effect of parenchymal volume preservation on kidney function after partial nephrectomy. *J Urol.* 2011; 186:405–10. [PubMed: 21680004]
48. Tobert CM, Boelkins B, Culver S, Mammen L, Kahnoski RJ, Lane BR. Surgeon assessment of renal preservation with partial nephrectomy provides information comparable to measurement of volume preservation with 3-dimensional image analysis. *J Urol.* 2014; 191:1218–24. [PubMed: 24211601]
49. Patel AR, Eggener SE. Warm ischemia less than 30 minutes is not necessarily safe during partial nephrectomy: every minute matters. *Urol Oncol.* 2011; 29:826–8. [PubMed: 22078406]
50. Choi JD, Park JW, Lee SY, et al. Does prolonged warm ischemia after partial nephrectomy under pneumoperitoneum cause irreversible damage to the affected kidney? *J Urol.* 2012; 187:802–6. [PubMed: 22245321]
51. Godoy G, Ramanathan V, Kanofsky JA, et al. Effect of warm ischemia time during laparoscopic partial nephrectomy on early postoperative glomerular filtration rate. *J Urol.* 2009; 181:2438–43. [PubMed: 19371905]
52. Lane BR, Novick AC, Babineau D, Fergany AF, Kaouk JH, Gill IS. Comparison of laparoscopic and open partial nephrectomy for tumor in a solitary kidney. *J Urol.* 2008; 179:847–51. [PubMed: 18221958]
53. Thompson RH, Lane BR, Lohse CM, et al. Every minute counts when the renal hilum is clamped during partial nephrectomy. *Eur Urol.* 2010; 58:340–5. [PubMed: 20825756]
54. Lane BR, Campbell SC, Demirjian S, Fergany AF. Surgically induced chronic kidney disease may be associated with a lower risk of progression and mortality than medical chronic kidney disease. *J Urol.* 2013; 189:1649–55. [PubMed: 23201493]
55. Novick AC. Renal hypothermia: in vivo and ex vivo. *Urol Clin North Am.* 1983; 10:637–44. [PubMed: 6356550]
56. Russo P. Partial nephrectomy for renal cancer (part II): the impact of renal ischaemia, patient preparation, surgical approaches, management of complications and utilization. *BJU Int.* 2010; 105:1494–507. [PubMed: 20553456]
57. Boylu, U.; Lee, BR.; Thomas, R. Renal anatomy, physiology and its clinical relevance to nephrectomy. In: Patel, VR., editor. *Robotic urologic surgery.* London: Springer; 2012. p. 269–76.
58. Power NE, Maschino AC, Savage C, et al. Intraoperative mannitol use does not improve long-term renal function outcomes after minimally invasive partial nephrectomy. *Urology.* 2012; 79:821–5. [PubMed: 22469577]

59. Omae K, Kondo T, Takagi T, et al. Mannitol has no impact on renal function after open partial nephrectomy in solitary kidneys. *Int J Urol*. 2014; 21:200–3. [PubMed: 23819791]
60. Abe T, Sazawa A, Harabayashi T, et al. Renal hypothermia with ice slush in laparoscopic partial nephrectomy: the outcome of renal function. *J Endourol*. 2012; 26:1483–8. [PubMed: 22984848]
61. Rogers CG, Ghani KR, Kumar RK, Jeong W, Menon M. Robotic partial nephrectomy with cold ischemia and on-clamp tumor extraction: recapitulating the open approach. *Eur Urol*. 2013; 63:573–8. [PubMed: 23183196]
62. Nguyen MM, Gill IS. Halving ischemia time during laparoscopic partial nephrectomy. *J Urol*. 2008; 179:627–32. [PubMed: 18082215]
63. Williams SB, Kacker R, Alemozaffar M, Francisco IS, Mechaber J, Wagner AA. Robotic partial nephrectomy versus laparoscopic partial nephrectomy: a single laparoscopic trained surgeon's experience in the development of a robotic partial nephrectomy program. *World J Urol*. 2013; 31:793–8. [PubMed: 21274541]
64. Benway BM, Baca G, Bhayani SB, et al. Selective versus nonselective arterial clamping during laparoscopic partial nephrectomy: impact upon renal function in the setting of a solitary kidney in a porcine model. *J Endourol*. 2009; 23:1127–33. [PubMed: 19514812]
65. Nohara T, Fujita H, Yamamoto K, Kitagawa Y, Gabata T, Namiki M. Modified anatomic partial nephrectomy with selective renal segmental artery clamping to preserve renal function: a preliminary report. *Int J Urol*. 2008; 15:961–6. [PubMed: 18808428]
66. Gill IS, Eisenberg MS, Aron M, et al. “Zero ischemia” partial nephrectomy: novel laparoscopic and robotic technique. *Eur Urol*. 2011; 59:128–34. [PubMed: 20971550]
67. Shao P, Qin C, Yin C, et al. Laparoscopic partial nephrectomy with segmental renal artery clamping: technique and clinical outcomes. *Eur Urol*. 2011; 59:849–55. [PubMed: 21146917]
68. Desai MM, de Castro Abreu AL, Leslie S, et al. Robotic partial nephrectomy with superselective versus main artery clamping: a retrospective comparison. *Eur Urol*. 2014; 66:713–9. [PubMed: 24486306]
69. Abreu AL, Gill IS, Desai MM. Zero-ischaemia robotic partial nephrectomy (RPN) for hilar tumours. *BJU Int*. 2011; 108:948–54. [PubMed: 21917096]
70. Ng CK, Gill IS, Patil MB, et al. Anatomic renal artery branch microdissection to facilitate zero-ischemia partial nephrectomy. *Eur Urol*. 2012; 61:67–74. [PubMed: 21908096]
71. Holzer MS, Best SL, Jackson N, et al. Assessment of renal oxygenation during partial nephrectomy using hyperspectral imaging. *J Urol*. 2011; 186:400–4. [PubMed: 21679994]
72. Olweny EO, Faddegon S, Best SL, et al. Renal oxygenation during robot-assisted laparoscopic partial nephrectomy: characterization using laparoscopic digital light processing hyperspectral imaging. *J Endourol*. 2013; 27:265–9. [PubMed: 22973969]
73. Tobis S, Knopf JK, Silvers C, et al. Robot-assisted and laparoscopic partial nephrectomy with near infrared fluorescence imaging. *J Endourol*. 2012; 26:797–802. [PubMed: 22250958]
74. Gill IS, Patil MB, Abreu AL, et al. Zero ischemia anatomical partial nephrectomy: a novel approach. *J Urol*. 2012; 187:807–14. [PubMed: 22248519]
75. Thompson RH, Frank I, Lohse CM, et al. The impact of ischemia time during open nephron sparing surgery on solitary kidneys: a multi-institutional study. *J Urol*. 2007; 177:471–6. [PubMed: 17222613]
76. Guillonnet B, Bermudez H, Gholami S, et al. Laparoscopic partial nephrectomy for renal tumor: single center experience comparing clamping and no clamping techniques of the renal vasculature. *J Urol*. 2003; 169:483–6. [PubMed: 12544293]
77. Smith GL, Kenney PA, Lee Y, Libertino JA. Non-clamped partial nephrectomy: techniques and surgical outcomes. *BJU Int*. 2011; 107:1054–8. [PubMed: 21040369]
78. Kaczmarek BF, Tanagho YS, Hillyer SP, et al. Off-clamp robot-assisted partial nephrectomy preserves renal function: a multi-institutional propensity score analysis. *Eur Urol*. 2013; 64:988–93. [PubMed: 23122834]
79. Simone G, Papalia R, Guaglianone S, Carpanese L, Gallucci M. Zero ischemia laparoscopic partial nephrectomy after superselective transarterial tumor embolization for tumors with moderate nephrometry score: long-term results of a single-center experience. *J Endourol*. 2011; 25:1443–6. [PubMed: 21797763]

80. Simone G, Papalia R, Guaglianone S, Forestiere E, Gallucci M. Preoperative superselective transarterial embolization in laparoscopic partial nephrectomy: technique, oncologic, and functional outcomes. *J Endourol.* 2009; 23:1473–8. [PubMed: 19694532]
81. Wu SD, Viprakasit DP, Cashy J, Smith ND, Perry KT, Nadler RB. Radiofrequency ablation-assisted robotic laparoscopic partial nephrectomy without renal hilar vessel clamping versus laparoscopic partial nephrectomy: a comparison of perioperative outcomes. *J Endourol.* 2010; 24:385–91. [PubMed: 20334556]
82. Viprakasit DP, Derweesh I, Wong C, et al. Selective renal parenchymal clamping in robot-assisted laparoscopic partial nephrectomy: a multi-institutional experience. *J Endourol.* 2011; 25:1487–91. [PubMed: 21902518]
83. Weight CJ, Lane BR, Gill IS. Laparoscopic partial nephrectomy for selected central tumours: omitting the bolster. *BJU Int.* 2007; 100:375–8. [PubMed: 17617142]
84. Hung AJ, Cai J, Simmons MN, Gill IS. “Trifecta” in partial nephrectomy. *J Urol.* 2013; 189:36–42. [PubMed: 23164381]
85. Breda A, Stepanian SV, Liao J, et al. Positive margins in laparoscopic partial nephrectomy in 855 cases: a multi-institutional survey from the United States and Europe. *J Urol.* 2007; 178:47–50. [PubMed: 17574057]
86. Uzzo RG, Novick AC. Nephron sparing surgery for renal tumors: indications, techniques and outcomes. *J Urol.* 2001; 166:6–18. [PubMed: 11435813]
87. Sutherland SE, Resnick MI, Maclennan GT, Goldman HB. Does the size of the surgical margin in partial nephrectomy for renal cell cancer really matter? *J Urol.* 2002; 167:61–4. [PubMed: 11743276]
88. Sundaram V, Figenshau RS, Roytman TM, et al. Positive margin during partial nephrectomy: does cancer remain in the renal remnant? *Urology.* 2011; 77:1400–3. [PubMed: 21411126]
89. Duvdevani M, Laufer M, Kastin A, et al. Is frozen section analysis in nephron sparing surgery necessary? A clinicopathological study of 301 cases. *J Urol.* 2005; 173:385–7. [PubMed: 15643176]
90. Laryngakis NA, Guzzo TJ. Tumor enucleation for small renal masses. *Curr Opin Urol.* 2012; 22:365–71. [PubMed: 22647650]
91. Minervini A, Serni S, Tuccio A, et al. Simple enucleation versus radical nephrectomy in the treatment of pT1a and pT1b renal cell carcinoma. *Ann Surg Oncol.* 2012; 19:694–700. [PubMed: 21861225]
92. Li QL, Guan HW, Zhang QP, Zhang LZ, Wang FP, Liu YJ. Optimal margin in nephron-sparing surgery for renal cell carcinoma 4 cm or less. *Eur Urol.* 2003; 44:448–51. [PubMed: 14499679]
93. Minervini A, di Cristofano C, Lapini A, et al. Histopathologic analysis of peritumoral pseudocapsule and surgical margin status after tumor enucleation for renal cell carcinoma. *Eur Urol.* 2009; 55:1410–8. [PubMed: 18692300]
94. Ficarra V, Bhayani S, Porter J, et al. Predictors of warm ischemia time and perioperative complications in a multicenter, international series of robot-assisted partial nephrectomy. *Eur Urol.* 2012; 61:395–402. [PubMed: 22079308]
95. Liu ZW, Olweny EO, Yin G, et al. Prediction of perioperative outcomes following minimally invasive partial nephrectomy: role of the R.E.N.A. L nephrometry score. *World J Urol.* 2013; 31:1183–9. [PubMed: 22544340]
96. Simhan J, Smaldone MC, Tsai KJ, et al. Objective measures of renal mass anatomic complexity predict rates of major complications following partial nephrectomy. *Eur Urol.* 2011; 60:724–30. [PubMed: 21621910]
97. Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective randomized EORTC intergroup phase 3 study comparing the complications of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. *Eur Urol.* 2007; 51:1606–15. [PubMed: 17140723]
98. Patard JJ, Pantuck AJ, Crepel M, et al. Morbidity and clinical outcome of nephron-sparing surgery in relation to tumour size and indication. *Eur Urol.* 2007; 52:148–54. [PubMed: 17240036]
99. Richstone L, Montag S, Ost MC, et al. Predictors of hemorrhage after laparoscopic partial nephrectomy. *Urology.* 2011; 77:88–91. [PubMed: 21195825]

100. Gill IS, Kavoussi LR, Lane BR, et al. Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. *J Urol.* 2007; 178:41–6. [PubMed: 17574056]
101. Tanagho YS, Kaouk JH, Allaf ME, et al. Perioperative complications of robot-assisted partial nephrectomy: analysis of 886 patients at 5 United States centers. *Urology.* 2013; 81:573–80. [PubMed: 23452807]
102. Breda A, Stepanian SV, Lam JS, et al. Use of haemostatic agents and glues during laparoscopic partial nephrectomy: a multi-institutional survey from the United States and Europe of 1347 cases. *Eur Urol.* 2007; 52:798–803. [PubMed: 17329015]
103. Gill IS, Ramani AP, Spaliviero M, et al. Improved hemostasis during laparoscopic partial nephrectomy using gelatin matrix thrombin sealant. *Urology.* 2005; 65:463–6. [PubMed: 15780356]
104. Richter F, Schnorr D, Deger S, et al. Improvement of hemostasis in open and laparoscopically performed partial nephrectomy using a gelatin matrix-thrombin tissue sealant (FloSeal). *Urology.* 2003; 61:73–7. [PubMed: 12559270]
105. Jeldres C, Bensalah K, Capitanio U, et al. Baseline renal function, ischaemia time and blood loss predict the rate of renal failure after partial nephrectomy. *BJU Int.* 2009; 103:1632–5. [PubMed: 19545272]
106. Stroup SP, Palazzi K, Kopp RP, et al. RENAL nephrometry score is associated with operative approach for partial nephrectomy and urine leak. *Urology.* 2012; 80:151–6. [PubMed: 22748871]
107. Bove P, Bhayani SB, Rha KH, Allaf ME, Jarrett TW, Kavoussi LR. Necessity of ureteral catheter during laparoscopic partial nephrectomy. *J Urol.* 2004; 172:458–60. [PubMed: 15247702]
108. Tomaszewski JJ, Cung B, Smaldone MC, et al. Renal pelvic anatomy is associated with incidence, grade, and need for intervention for urine leak following partial nephrectomy. *Eur Urol.* 2014; 66:949–55. [PubMed: 24184023]
109. Tomaszewski JJ, Smaldone MC, Cung B, et al. Internal validation of the renal pelvic score: a novel marker of renal pelvic anatomy that predicts urine leak after partial nephrectomy. *Urology.* 2014; 84:351–7. [PubMed: 24975712]
110. Buffi N, Lista G, Larcher A, et al. Re: “Trifecta” in partial nephrectomy: A.J. Hung, J. Cai, M.N. Simmons and I.S. Gill *J Urol* 2013;189:36–42. *J Urol.* 2013; 190:810–1. [PubMed: 23434941]
111. Khalifeh A, Autorino R, Hillyer SP, et al. Comparative outcomes and assessment of trifecta in 500 robotic and laparoscopic partial nephrectomy cases: a single surgeon experience. *J Urol.* 2013; 189:1236–42. [PubMed: 23079376]
112. Hayn MH, Schwaab T, Underwood W, Kim HL. RENAL nephrometry score predicts surgical outcomes of laparoscopic partial nephrectomy. *BJU Int.* 2011; 108:876–81. [PubMed: 21166761]
113. Kruck S, Anastasiadis AG, Walcher U, Stenzl A, Herrmann TR, Nagele U. Laparoscopic partial nephrectomy: risk stratification according to patient and tumor characteristics. *World J Urol.* 2012; 30:639–46. [PubMed: 22270261]
114. Long JA, Arnoux V, Fiard G, et al. External validation of the RENAL nephrometry score in renal tumours treated by partial nephrectomy. *BJU Int.* 2013; 111:233–9. [PubMed: 22788546]
115. Mayer WA, Godoy G, Choi JM, Goh AC, Bian SX, Link RE. Higher RENAL Nephrometry Score is predictive of longer warm ischemia time and collecting system entry during laparoscopic and robotic-assisted partial nephrectomy. *Urology.* 2012; 79:1052–6. [PubMed: 22546382]
116. Altunrende F, Laydner H, Hernandez AV, et al. Correlation of the RENAL nephrometry score with warm ischemia time after robotic partial nephrectomy. *World J Urol.* 2013; 31:1165–9. [PubMed: 22527672]
117. Mufarrij PW, Krane LS, Rajamahanty S, Hemal AK. Does nephrometry scoring of renal tumors predict outcomes in patients selected for robot-assisted partial nephrectomy? *J Endourol.* 2011; 25:1649–53. [PubMed: 21851270]
118. Bruner B, Breau RH, Lohse CM, Leibovich BC, Blute ML. Renal nephrometry score is associated with urine leak after partial nephrectomy. *BJU Int.* 2011; 108:67–72. [PubMed: 21087391]
119. Waldert M, Waalkes S, Klatte T, et al. External validation of the preoperative anatomical classification for prediction of complications related to nephron-sparing surgery. *World J Urol.* 2010; 28:531–5. [PubMed: 20607246]

120. Kong W, Zhang J, Dong B, et al. Application of a standardized anatomical classification in a Chinese partial nephrectomy series. *Int J Urol.* 2012; 19:551–8. [PubMed: 22462720]
121. Mottrie A, Schatteman P, De Wil P, De Troyer B, Novara G, Ficarra V. Validation of the preoperative aspects and dimensions used for an anatomical (PADUA) score in a robot-assisted partial nephrectomy series. *World J Urol.* 2013; 31:799–804. [PubMed: 21286726]
122. Tyrirtzis SI, Papadoukakis S, Katafigiotis I, et al. Implementation and external validation of Preoperative Aspects and Dimensions Used for an Anatomical (PADUA) score for predicting complications in 74 consecutive partial nephrectomies. *BJU Int.* 2012; 109:1813–8. [PubMed: 21981696]
123. Minervini A, Vittori G, Salvi M, et al. analysis of surgical complications of renal tumor enucleation with standardized instruments and external validation of PADUA classification. *Ann Surg Oncol.* 2013; 20:1729–36. [PubMed: 23263701]


### Take Home Message

Surgical renal anatomy underpins imaging, nephrometry scoring systems, and novel vascular control techniques that reduce global renal ischemia and may impact postoperative renal function. A contemporary ideal partial nephrectomy excises the tumor with a thin negative margin, delicately secures the tumor bed to maximize vascularized remnant parenchyma, and reduces global ischemia to the renal remnant with minimal complications.






**Fig. 1.** Computed tomography scan showing two right renal arteries. Courtesy of V. Ficarra, University of Udine, and V. Macchi, University of Padua.



**Fig. 2.** Anatomy of the left renal artery. Extra- and intraparenchymal arterial sections are distinguished. Courtesy of V. Ficarra, University of Udine, and V. Macchi, University of Padua.



**Fig. 3.** Graves' anatomic classification of segmental renal arteries. In addition to the classical variant, a high percentage of patients show anatomic variations. Courtesy of V. Ficarra, University of Udine, and V. Macchi, University of Padua.

**Table 1**

Overview of the parameters of the RENAL and PADUA scoring systems

Variable	RENAL	PADUA
Maximal tumor diameter	1 point: 4 cm	1 point: 4 cm
	2 points: >4 – <7 cm	2 points: 4–7 cm
	3 points: 7 cm	3 points: >7 cm
Exophytic/endophytic rate	1 point: 50%	1 point: 50%
	2 points: <50%	2 points: <50%
	3 points: endophytic	3 points: endophytic
Collecting system	Or renal sinus	1 point: not involved
	1 point: proximity >7 mm	2 points: dislocated/infiltrated
	2 points: proximity 4–7 mm	
Polar location	3 points: proximity 4 mm	
	1 point: entirely above or below the polar lines	1 point: superior/inferior <sup>b</sup>
	2 points: crosses the polar line	2 points: middle
Renal rim	3 points: >50% crosses the polar line or crosses the axial renal midline or entirely between the polar lines	
	–	1 point: lateral
		2 point: medial
Renal sinus	Included in collecting system	1 point: not involved
		2 points: involved
Anterior/posterior	No points	No points

<sup>a</sup>Polar lines are defined as the plane of the kidney above or below which the medial lip of parenchyma is interrupted by the renal sinus fat, vessels, or the collecting system on axial imaging.

<sup>b</sup>Polar lines are defined according to the renal sinus.

**Table 2**  
Selected validation studies for the RENAL score, PADUA classification, and C index

Reference	n	Complications	Ischemia time	Blood loss	LOS
<b>RENAL score</b>					
Hayn et al [112]	141 LPN	NS	+	+	+
Simhan et al [96]	216 OPN, 174 RPN	Major (CCS 3–5)	+	+	+
Hew et al [33]	134 PN	+	+	NA	NA
Kruck et al [113]	81 LPN	NS	NS	+	+
Lavallée et al [35]	78 OPN	NA	+	NA	NA
Bylund et al [32]	124 LPN, 25 RPN, 13 OPN	NA	+	+	NA
Png et al [36]	83 RPN	NS	+	NS	NA
Long et al [114]	159 OPN, 18 LPN	NS	NS	NS	NS
Stroup et al [106]	153 OPN, 100 LPN, 31 RPN	Urine leak, but NS overall	NA	NA	NA
Mayer et al [115]	55 RPN, 12 LPN	NA	+	NS	NA
Liu et al [95]	128 LPN, 53 RPN	+	+	NS	NS
Aitunrende et al [116]	181 RPN	NA	NS	NA	NA
Mufarrij et al [117]	92 RPN	NS	Trend ( $p = 0.07$ )	Trend ( $p = 0.07$ )	NS
Bruner et al [118]	155 PN	Urine leak	NA	NA	NA
Okhunov et al [34]	101 LPN	NS	+	NS	NS
<b>PADUA classification</b>					
Hew et al [33]	134 PN	+	+	NA	NA
Kruck et al [113]	81 LPN	-	NS	+	+
Lavallée et al [35]	78 OPN	NA	+	NA	NA
Bylund et al [32]	124 LPN, 25 RPN, 13 OPN	NA	+	NS	NA
Okhunov et al [34]	101 LPN	NS	+	NS	NS
Ficarra et al [94]	347 RPN	+	+	+	NA
Waldert et al [119]	186 OPN, 54 LPN	+	+	NA	NA
Kong et al [120]	136 OPN, 59 LPN	+	+	NS	NA
Mottrie et al [121]	62 RPN	+	+	+	NA
Tyritzis et al [122]	74 OPN	+	NA	NA	NA
Minervini et al [123]	244 OPN	+	NA	NA	NA

Reference	n	Complications	Ischemia time	Blood loss	LOS
<b>C index</b>					
Lavallée et al [35]	78 OPN	NA	Trend ( $p = 0.06$ )	NA	NA
Bylund et al [32]	124 LPN, 25 RPN, 13 OPN	NA	+	NS	NA
Okhunov et al [34]	101 LPN	NS	+	NS	+

LOS = length of hospital stay; LPN = laparoscopic partial nephrectomy; OPN = open partial nephrectomy; RPN = robot-assisted partial nephrectomy; + = statistically significant association; NS = not significant; NA = not assessed; CCS = Clavien-Dindo classification system.